Key result
Review tackles trial controversies around multiplicity and subgroups to guide balanced reporting.
Why the study?
Several statistical controversies commonly arise when reporting major clinical trials, affecting interpretation and quality of trial reports.
Design
Review of statistical controversies in clinical trial reporting with cardiology examples
Answers are grounded in this paper and cite their sources.
Provides methodological guidance on handling statistical controversies in the reporting of cardiology clinical trials.
This paper tackles several statistical controversies that are commonly faced when reporting a major clinical trial. Topics covered include: multiplicity of data, interpreting secondary endpoints and composite endpoints, the value of covariate adjustment, the traumas of subgroup analysis, assessing individual benefits and risks, alternatives to analysis by intention to treat, interpreting surprise findings (good and bad), and the overall quality of clinical trial reports. All is put in the context of topical cardiology trial examples and is geared to help trialists steer a wise course in their statistical reporting, thereby giving readers a balanced account of trial findings.
No takes yet. Share an insight, caveat, or question.
Pocock et al. (2015) reported a review. This review discusses statistical controversies in reporting clinical trials, including multiplicity, subgroup analysis, and intention-to-treat alternatives, to guide trialists in balanced reporting.
Synapse has enriched 10 related papers. Consider them for comparative context: